Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma

This study has been withdrawn prior to enrollment.
(Modifications will be necessary before full IRB approval will be secured.)
Information provided by:
NeoPlas Innovation Identifier:
First received: August 20, 2009
Last updated: September 4, 2009
Last verified: September 2009
The purpose of this study is to determine whether an outpatient combination of lovastatin and low-to-moderate dose interferon is effective in the treatment of patients with malignant melanoma.

Condition Intervention Phase
Malignant Melanoma
Drug: lovastatin
Drug: interferon alfa-2b
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 2 Study of Interferon Alfa-2b and Lovastatin Combination Therapy for Patients With High-risk Resected or Unresectable Malignant Melanoma

Resource links provided by NLM:

Further study details as provided by NeoPlas Innovation:

Primary Outcome Measures:
  • Overall survival [ Time Frame: 6 months, 1 yr, 2 yr, 3 yr, 4 yr, 5 yr ]
  • Time to progression of disease [ Time Frame: 2 mos, 4 mos, 6 mos, 1 yr, 2 yr, 3 yr, 4 yr, 5 yr ]

Secondary Outcome Measures:
  • Appearance of new distant metastases [ Time Frame: 2 mos, 4 mos, 6 mos, 1 yr, 2 yr, 3 yr, 4 yr, 5 yr ]
  • Toleration of medication side effects and quality of life [ Time Frame: 4 mos, 1 yr, 2 yr, 3 yr, 4 yr, 5 yr ]

Estimated Enrollment: 250
Study Start Date: December 2009
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Interferon and lovastatin treatment
Patients receive outpatient treatment with lovastatin (oral) and interferon alfa-2b (subcutaneous injection) as per protocol parameters.
Drug: lovastatin
lovastatin tablets, oral administration, daily dose 1.5 mg/kg, divided into three or four essentially equal doses with meals
Other Name: Mevacor
Drug: interferon alfa-2b
interferon alfa-2b for subcutaneous injection, each injection 100,000 international units per kg body mass, three injections weekly
Other Name: Intron-A

Detailed Description:

Malignant melanoma, or simply melanoma, is a potentially fatal cancer which begins as a skin cancer and can spread very aggressively. The incidence of melanoma has been rising rapidly over the last decade and it is now becoming a serious health threat in young adults as well as older adults. Unfortunately, if melanoma escapes complete surgical removal, there are very few treatments which have been found very effective in controlling its growth and spread. If the cancer spreads to the lymph node system or beyond, the chances for long-term survival can be very poor.

This study proposes to test the effectiveness for melanoma treatment of a combination of two medicines which are in widespread use for other medical conditions. Interferon alfa-2b (also known simply as interferon or by a brand name Intron-A) is an exact replica of a protein produced by the human immune system. The human body makes this immune system regulator to help it kill cells in the body which are damaged or infected and thus need to be removed before they can cause further harm to the body. This medicine is often prescribed for infections like hepatitis, some types of cancer including melanoma, and immune system disorders. This study uses interferon in moderate doses, much less than typically used for melanoma treatment when it is used alone, and so the side effects of treatment may be milder. The other medicine being used in combination with it is lovastatin. This medicine is most often used to help patients reduce their cholesterol levels and therefore reduce the risk of heart attacks and strokes. Millions of people use this medicine because it has been found very safe and effective. Research has shown that it also has significant effects against the growth of cancer cells in laboratory cultures and in some animal models.

These two medicines have been used together to treat patients with cancer for several years in our medical practice, but until now they have not been formally tested in a clinical trial. This study will test how well the combination of these medicines can perform and test the hypothesis that they can achieve better survival and control of disease than currently available standard treatment. The incidence of side effects and other details will be monitored too.

This study is open to qualifying patients with stage 2, 3, or 4 melanoma. The results for patients in each group will be compared to other patients in the study with the same or similar stage of disease and with historical results of patients receiving the standard, already-approved treatments for similar stages of melanoma.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria: (patients must meet all these criteria)

  • Histologically confirmed diagnosis of malignant melanoma
  • AJCC stage 2, 3, or 4 disease subject to the planned patient enrollment numbers for this trial
  • Surgical resection to the extent possible
  • ECOG performance status of 0, 1, or 2
  • Expected survival of six months or greater
  • ALT (SGPT) and AST (SGOT) not greater than 2.5x upper limit of normal range
  • CT, PET or other valid imaging sufficient to demonstrate extent of disease performed less than three weeks prior to initiation or less than two weeks following initiation
  • Female patients of childbearing potential must agree to practice contraception, abstinence, or other effective pregnancy avoidance measures while enrolled in this trial and for one month afterward

Exclusion Criteria: (patients meeting any of these criteria are ineligible)

  • Current or anticipated pregnancy or breastfeeding
  • History of or evidence suggestive of cerebral metastatic disease
  • Impaired ability to absorb nutrition and/or medications normally via gastrointestinal tract
  • Less than 18 years of age
  • History or evidence of cirrhosis, chronic hepatitis, pancreatitis, or other significant hepatobiliary impairment
  • History or evidence of HIV infection or other immune system impairment
  • History of organ or tissue transplant requiring immunosuppressive therapy
  • History of neutropenia other than that induced by chemotherapy
  • Cytotoxic chemotherapy or radiation treatment within three weeks prior to initiation
  • Presence of greater than six identifiable tumors counting all primary and metastatic lesions
  • Presence of any single tumor mass greater than 6 cm in greatest dimension
  • Presence of three or more tumor masses greater than 4 cm in greatest dimension
  • Chronic steroid or immunosuppressive therapy
  • Any other serious medical condition which, in the medical opinion of the investigator, limits life expectancy to two years or less or has significant potential for debilitation
  • Any condition, psychiatric or otherwise, which may preclude valid informed consent or consistent compliance with study requirements in the medical opinion of the investigator
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00963664

United States, Tennessee
NeoPlas Innovation
Nashville, Tennessee, United States, 37027
Sponsors and Collaborators
NeoPlas Innovation
Principal Investigator: Stephen B. Cantrell, MD NeoPlas Innovation
  More Information

Responsible Party: Stephen B. Cantrell MD, Director of Research, NeoPlas Innovation Identifier: NCT00963664     History of Changes
Other Study ID Numbers: NI-MM-009
Study First Received: August 20, 2009
Last Updated: September 4, 2009

Keywords provided by NeoPlas Innovation:
malignant melanoma
interferon alfa-2b
Intron A

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
L 647318
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors processed this record on April 26, 2017